<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Drugs R D</journal-id>
      <journal-id journal-id-type="iso-abbrev">Drugs R D</journal-id>
      <journal-title-group>
        <journal-title>Drugs in R&amp;D</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1174-5886</issn>
      <issn pub-type="epub">1179-6901</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24962606</article-id>
      <article-id pub-id-type="pmc">4070464</article-id>
      <article-id pub-id-type="publisher-id">50</article-id>
      <article-id pub-id-type="doi">10.1007/s40268-014-0050-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Etanercept-Associated Transient Bone Marrow Aplasia: A Review of the Literature and Pathogenetic Mechanisms</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kozak</surname>
            <given-names>Natasha</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Friedman</surname>
            <given-names>Joshua</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Schattner</surname>
            <given-names>Ami</given-names>
          </name>
          <address>
            <phone>972-8-939-0330</phone>
            <email>amiMD@clalit.org.il</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Medicine, Kaplan Medical Center, POB 1, Rehovot, 76100 Israel </aff>
        <aff id="Aff2"><label/>The Faculty of Medicine, Hebrew University and Hadassah, Jerusalem, Israel </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>11</day>
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <issue>2</issue>
      <fpage>155</fpage>
      <lpage>158</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2014</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>A patient with rheumatoid arthritis presented with increasing fatigue, fever, gingival bleeding, and petechial rash. Her symptoms started 1 week after the first injection of etanercept (Enbrel). Her only other medications (methotrexate and hydroxychloroquine) had been unchanged for years. Tests revealed severe pancytopenia and bone marrow aplasia. She recovered with supportive treatment within 12&#xA0;days. The literature on serious blood dyscrasias associated with anti-tumor necrosis factor-&#x3B1; therapy is reviewed, an intriguing postulated mechanism is discussed, and selective patient monitoring is recommended.</p>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer International Publishing Switzerland 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="intro">
      <title>Introduction</title>
      <p>With the increasing use of agents that block the action of tumor necrosis factor (TNF)-&#x3B1; in the treatment of rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory conditions, recognition of serious adverse events assumes greater importance even when they are rare [<xref ref-type="bibr" rid="CR1">1</xref>]. We report a patient with RA who presented with transient bone marrow (BM) aplasia associated with the first injection of etanercept, and review the literature on TNF-blocking agent-associated cytopenias.</p>
    </sec>
    <sec id="Sec2">
      <title>Report of a Case</title>
      <p>A 62-year-old woman was admitted with fatigue, fever (39&#xA0;&#xB0;C), gingival bleeding, and a rash over her legs.</p>
      <p>She had a history of RA diagnosed 6&#xA0;years prior when marked synovitis in more than ten large and small joints was found, associated with prolonged morning stiffness, elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and strongly positive rheumatoid factor and anti-citrullinated peptide antibodies (250&#xA0;IU/ml and 76.6, respectively).</p>
      <p>Her recent treatment included methotrexate (22.5&#xA0;mg once a week with daily folic acid) started on diagnosis, hydroxychloroquine (200&#xA0;mg daily) and a single first injection of etanercept (Enbrel<sup>&#xAE;</sup> 50&#xA0;mg) administered subcutaneously into the thigh 23&#xA0;days prior to admission.</p>
      <p>Previous treatment with leflunomide and adalimumab (Humira<sup>&#xAE;</sup>) had failed and been discontinued months before etanercept was started.</p>
      <p>No other medications were used, and even methotrexate and hydroxychloroquine were discontinued by her rheumatologist when etanercept was commenced.</p>
      <p>One week after the injection, she reported malaise, lassitude, and low-grade fever; those symptoms persisted over 2&#xA0;weeks.</p>
      <p>A sudden appearance of high fever and rash led to her admission.</p>
      <p>On admission, she was febrile and tachycardic but stable, with unrewarding examination except for gingival bleeding, a profuse petechial rash over both legs and polysynovitis, which was not new.</p>
      <p>Laboratory tests showed hemoglobin (Hb) 7.5&#xA0;g/dl (normocytic), WBC 1.8&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L with absolute neutrophil count (ANC) 0.7&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L, platelets 3&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L, ESR 172&#xA0;mm/h, CRP 76.8&#xA0;mg/dL (normal &lt;6&#xA0;mg/dL), albumin 26&#xA0;g/L, and globulins 47&#xA0;g/L (polyclonal). Serum creatinine, electrolytes, and liver enzymes were normal. Peripheral blood smear confirmed severe pancytopenia with absent reticulocytes (0.3&#xA0;%). Bone marrow aspiration and biopsy revealed BM aplasia (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Methotrexate in serum was undetectable. Chest X-ray, urinalysis, and cultures were normal. Tests for other causes of cytopenias, including serology for Epstein&#x2013;Barr virus (EBV), cytomegalovirus (CMV), hepatitis viruses, parvovirus B-19, and HIV were negative.<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Patient&#x2019;s bone marrow biopsy showing stroma and plasma cells (more resistant to drug toxicity) but absence of all other hematopoietic elements, consistent with transient aplasia</p></caption><graphic xlink:href="40268_2014_50_Fig1_HTML" id="MO1"/></fig></p>
      <p>The patient was treated with platelets (four times), packed cells (4&#xA0;U), granulocyte colony-stimulating factor (Neupogen<sup>&#xAE;</sup>) over 5&#xA0;days, and broad-spectrum antibiotics. She was discharged on the 12th hospital day, afebrile and stable (absolute neutrophil count [ANC] 10.5&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L), for ambulatory follow-up.</p>
      <p>One month later, the Hb was 12.4&#xA0;g/dL, white blood count (WBC) 13.7&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L, and platelets 149&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L. The patient resumed methotrexate treatment uneventfully for more than 6&#xA0;months of follow-up.</p>
    </sec>
    <sec id="Sec3">
      <title>Discussion and Review of the Literature</title>
      <p>When serious adverse events (SAEs) associated with anti-TNF&#x3B1; therapy are considered, attention is usually focused on an increased risk of infections (in particular, reactivation of tuberculosis and opportunistic infections) and malignancy, though the latter remains an unresolved concern [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>However, anti-TNF&#x3B1; therapy-induced cytopenias constitute another SAE that are potentially life threatening and mandate better recognition. For example, neutropenia was reported in 14.3&#x2013;18.8&#xA0;% of patients receiving a TNF&#x3B1; inhibitor [<xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref>]. In most of the patients, neutropenia occurred after just 2&#xA0;weeks of treatment, was mild (mean &#x2212;1.1&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L), transient, and showed spontaneous resolution, allowing the original treatment to be continued in most (81&#xA0;%) patients. However, a few patients developed serious secondary infections (4/367, 1.1&#xA0;%) [<xref ref-type="bibr" rid="CR5">5</xref>]. Notably, asymptomatic drops in platelet counts (mean &#x2212;28&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L) were often associated [<xref ref-type="bibr" rid="CR5">5</xref>]. Indeed, 19 patients with significant thrombocytopenia were identified in a recent review of the literature and, as in the case of neutropenia, almost all were due to either etanercept or infliximab [<xref ref-type="bibr" rid="CR6">6</xref>]. No other concomitant medication was reported in most of the patients. Rarely, patients may develop both severe neutropenia and thrombocytopenia [<xref ref-type="bibr" rid="CR7">7</xref>], whereas anemia is not usually a feature of this treatment. On the contrary, with amelioration of the underlying disease on anti-TNF&#x3B1; therapy, the often-present anemia of chronic inflammation frequently improves [<xref ref-type="bibr" rid="CR8">8</xref>]. However, this therapy, especially etanercept and infliximab, may mediate a more life-threatening adverse event than neutropenia or thrombocytopenia, namely, aplastic anemia and pancytopenia. A few such patients have been identified in post-marketing reports, although the attribution of pancytopenia to the TNF inhibitor remains unclear [<xref ref-type="bibr" rid="CR9">9</xref>]. The characteristics of all fully reported cases are summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. Thus, etanercept and infliximab have been linked so far to just one case of aplastic anemia each, and several patients had developed pancytopenia or aplastic anemia, which could well have been related to anti-TNF&#x3B1; therapy [<xref ref-type="bibr" rid="CR11">11</xref>&#x2013;<xref ref-type="bibr" rid="CR16">16</xref>]. Most affected patients had RA, and the hematological SAE occurred predominantly after the first TNF&#x3B1; antagonist doses, becoming symptomatic soon after and usually responsive to drug discontinuation and supportive treatment (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Potentially life-threatening non-malignant hematological complications associated with tumor necrosis factor-inhibitor therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patients<break/>References</th><th align="left">Background</th><th align="left">Treatment</th><th align="left">Other potential drugs</th><th align="left">SAEs</th><th align="left">Time interval</th><th align="left">Outcome</th><th align="left">Remarks</th></tr></thead><tbody><tr><td align="left">4/367 pts<break/>[<xref ref-type="bibr" rid="CR5">5</xref>]</td><td align="left">Varied</td><td align="left">Varied</td><td align="left">Unlikely</td><td align="left">Severe neutropenia with serious infection</td><td align="left">NR</td><td align="left">Recovered</td><td align="left">BM &#x2018;normal&#x2019; in 2 cases</td></tr><tr><td align="left">20M<break/>[<xref ref-type="bibr" rid="CR10">10</xref>]</td><td align="left">Crohn&#x2019;s spondylarthritis</td><td align="left">Infliximab [2nd]</td><td align="left">None</td><td align="left">Agranulocytosis</td><td align="left">NR</td><td align="left">Resolved, recurred after retreatment</td><td align="left">Granulocyte Bound Ab and neutrophil-specific bound Ab</td></tr><tr><td align="left">60F<break/>[<xref ref-type="bibr" rid="CR7">7</xref>]</td><td align="left">RA</td><td align="left">Infliximab [3rd]</td><td align="left">Unlikely</td><td align="left">Fever/chills and skin hemorrhages: profound neutropenia and thrombocytopenia</td><td align="left">7&#xA0;weeks</td><td align="left">Resolved</td><td align="left">BM Bx: hypoplasia</td></tr><tr><td align="left">2/61 pts<break/>[<xref ref-type="bibr" rid="CR11">11</xref>]</td><td align="left">Juvenile Id. arthritis</td><td align="left">Etanercept [1st in 1 pt]</td><td align="left">Unlikely</td><td align="left">Pancytopenia</td><td align="left">0.5; 12&#xA0;months</td><td align="left">Resolved</td><td align="left">Open-label prospective study</td></tr><tr><td align="left">45F<break/>[<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">Scleroderma</td><td align="left">Infliximab [1st]</td><td align="left">None</td><td align="left">Severe pancytopenia and candida peritonitis</td><td align="left">3&#xA0;weeks</td><td align="left">Died</td><td align="left">Transient HS reaction at 6&#xA0;days</td></tr><tr><td align="left">78M<break/>[<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="left">RA</td><td align="left">Etanercept (&gt;17th dose)</td><td align="left">Unlikely</td><td align="left">Aplastic anemia and sepsis</td><td align="left">&lt;3&#xA0;months</td><td align="left">Resolved over 3&#xA0;weeks</td><td align="left">BM Bx+</td></tr><tr><td align="left">66M<break/>[<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="left">RA</td><td align="left">Infliximab [1st]</td><td align="left">Possible</td><td align="left">Severe pancytopenia and BM hypoplasia with sepsis</td><td align="left">10&#xA0;days</td><td align="left">Resolved over 2&#xA0;weeks</td><td align="left">BM Bx+</td></tr><tr><td align="left">32F<break/>[<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="left">Colitis</td><td align="left">Infliximab [1st]</td><td align="left">Possible (IV ATB)</td><td align="left">Severe pancytopenia</td><td align="left">6&#xA0;days</td><td align="left">Resolved over 2&#xA0;weeks</td><td align="left"/></tr><tr><td align="left">32NR<break/>[<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="left">Ankylosing spondylitis</td><td align="left">Infliximab [1st]</td><td align="left">None</td><td align="left">Aplastic anemia</td><td align="left">4&#xA0;days</td><td align="left">Resolved over 16&#xA0;days</td><td align="left">Associated skin vasculitis&#xA0;BM Bx+</td></tr><tr><td align="left">62F<break/>Current</td><td align="left">RA</td><td align="left">Etanercept [1st]</td><td align="left">Unlikely</td><td align="left">Transient BM aplasia</td><td align="left">2&#xA0;weeks</td><td align="left">Resolved over 12&#xA0;days</td><td align="left">BM Bx+</td></tr></tbody></table><table-wrap-foot><p>
<italic>Ab</italic> antibodies, <italic>BM</italic> bone marrow, <italic>Bx</italic> biopsy, <italic>F</italic> female, <italic>HS</italic> hypersensitivity, <italic>Id.</italic> idiopathic, <italic>IV ATB</italic> intravenous antibiotics, <italic>M</italic> male, <italic>NR</italic> not reported, <italic>pt(s)</italic> patient(s), <italic>RA</italic> rheumatoid arthritis, <italic>SAE</italic> serious adverse event, + postive</p></table-wrap-foot></table-wrap></p>
      <p>Our patient presented with symptoms and signs related to all three cytopenias: fatigue (due to anemia); fever that responded to broad spectrum antibiotics (due to severe neutropenia); and petechiae and gingival bleeding (due to severe thrombocytopenia). The absence of concomitant drugs (she had been receiving methotrexate and hydroxychloroquine for years) as well as the temporal relationship between the appearance of her symptoms and the first injection of etanercept, strongly suggest a causal link. Moreover, BM recovery from toxic injury corresponded to the discontinuation of etanercept, whereas methotrexate was later continued uneventfully for months. In contrast, in some of the other cases cited, drugs other than anti-TNF&#x3B1; could have been responsible.</p>
      <p>Other than listing all hitherto-reported cases of TNF blocking agent-associated aplastic anemia and pancytopenia, the literature review reveals the rarity of the association, considering that hundreds of thousands of patients have been treated. The other striking feature is the complexity of the pathogenesis. TNF&#x3B1; is a pleiotropic cytokine, part of a complex cytokine network that regulates hematopoiesis and may affect BM stem cells differently under different circumstances [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. On one hand, TNF&#x3B1; (and interferon &#x3B3;) are overexpressed in the BM of patients with acquired aplastic anemia and can be involved in BM stem cell apoptosis and suppression of erythropoiesis [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Thus, treatment with TNF&#x3B1; antagonists can be a useful approach to the treatment of refractory aplastic anemia [<xref ref-type="bibr" rid="CR21">21</xref>&#x2013;<xref ref-type="bibr" rid="CR23">23</xref>]. On the other hand, under different conditions, TNF&#x3B1; interacting with other cytokines directly enhances the clonal growth of BM progenitors and suppresses hematopoietic stem cell apoptosis [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Thus, its blockade can also exert a deleterious effect on hematopoiesis [<xref ref-type="bibr" rid="CR6">6</xref>]. Since autoimmune mechanisms are believed to have a key role in the pathogenesis of idiopathic aplastic anemia [<xref ref-type="bibr" rid="CR25">25</xref>], the association between TNF-targeted therapies and induction of autoimmune diseases (particularly, vasculitis and lupus predominantly with infliximab and etanercept) is also a tenable mechanism [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p>In conclusion, TNF&#x3B1; antagonists for the treatment of RA show significant benefit and are generally safe in comparison with other disease-modifying anti-rheumatic drugs [<xref ref-type="bibr" rid="CR27">27</xref>&#x2013;<xref ref-type="bibr" rid="CR29">29</xref>]. BM suppression resulting in severe cytopenia, transient pancytopenia, or aplastic anemia is a well established but fortunately rare SAE of anti-TNF&#x3B1; therapy. Since a steadily increasing number of patients are being treated for longer periods, any serious adverse effect, however rare, may be encountered.</p>
      <p>Monitoring blood counts of patients starting treatment seems advisable, and we also suggest that patients should be instructed to consult their physician when unexplained fever, fatigue, or bleeding manifestations appear.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Conflict of interest</title>
      <p>The authors confirm that they have no conflict of interest in connection with this manuscript.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hyrich</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Silman</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Symmons</surname>
              <given-names>DPM</given-names>
            </name>
          </person-group>
          <article-title>Anti-tumour necrosis factor &#x3B1; therapy in rheumatoid arthritis: an update on safety</article-title>
          <source>Ann Rheum Dis</source>
          <year>2004</year>
          <volume>63</volume>
          <fpage>1538</fpage>
          <lpage>1543</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2004.024737</pub-id>
          <pub-id pub-id-type="pmid">15242866</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burmester</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Panaccione</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>KB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn&#x2019;s disease</article-title>
          <source>Ann Rheum Dis</source>
          <year>2013</year>
          <volume>72</volume>
          <fpage>517</fpage>
          <lpage>524</lpage>
          <pub-id pub-id-type="doi">10.1136/annrheumdis-2011-201244</pub-id>
          <pub-id pub-id-type="pmid">22562972</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rajakulendran</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gadsby</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis</article-title>
          <source>Ann Rheum Dis</source>
          <year>2006</year>
          <volume>65</volume>
          <fpage>1678</fpage>
          <lpage>1679</lpage>
          <pub-id pub-id-type="doi">10.1136/ard.2006.056176</pub-id>
          <pub-id pub-id-type="pmid">17105865</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bathon</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Fleischmann</surname>
              <given-names>RM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis</article-title>
          <source>N Engl J Med</source>
          <year>2000</year>
          <volume>343</volume>
          <fpage>1586</fpage>
          <lpage>1593</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM200011303432201</pub-id>
          <pub-id pub-id-type="pmid">11096165</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hastings</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Butt</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neutropenia in patients receiving anti-tumor necrosis factor therapy</article-title>
          <source>Arthritis Care Res (Hoboken)</source>
          <year>2010</year>
          <volume>62</volume>
          <fpage>764</fpage>
          <lpage>769</lpage>
          <pub-id pub-id-type="doi">10.1002/acr.20037</pub-id>
          <pub-id pub-id-type="pmid">20535786</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bessissow</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Renard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoffman</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy</article-title>
          <source>Aliment Pharmacol Ther</source>
          <year>2012</year>
          <volume>36</volume>
          <fpage>312</fpage>
          <lpage>323</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2036.2012.05189.x</pub-id>
          <pub-id pub-id-type="pmid">22725726</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vidal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fontova</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Richart</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Severe neutropenia and thrombocytopenia associated with infliximab</article-title>
          <source>Ann Intern Med</source>
          <year>2003</year>
          <volume>139</volume>
          <fpage>E238</fpage>
          <lpage>E239</lpage>
          <pub-id pub-id-type="doi">10.7326/0003-4819-139-3-200308050-00021-w4</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furst</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Kay</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wasko</surname>
              <given-names>MC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis</article-title>
          <source>Rheumatology (Oxford)</source>
          <year>2013</year>
          <volume>52</volume>
          <fpage>1845</fpage>
          <lpage>1855</lpage>
          <pub-id pub-id-type="doi">10.1093/rheumatology/ket233</pub-id>
          <pub-id pub-id-type="pmid">23838027</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="other">US FDA. Safety update on TNF-&#x3B1; antagonists: infliximab and etanercept. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf">http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf</ext-link>.</mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Favalli</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Varenna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sinigaglia</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy</article-title>
          <source>Clin Exp Rheum</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>247</fpage>
          <lpage>250</lpage>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quartier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Taupinv</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bourdeaut</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type</article-title>
          <source>Arthritis Rheum</source>
          <year>2003</year>
          <volume>48</volume>
          <fpage>1093</fpage>
          <lpage>1101</lpage>
          <pub-id pub-id-type="doi">10.1002/art.10885</pub-id>
          <pub-id pub-id-type="pmid">12687553</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menon</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cucurulli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Espinoza</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
          <article-title>Pancytopenia in a patient with scleroderma treated with infliximab</article-title>
          <source>Rheumatology</source>
          <year>2003</year>
          <volume>42</volume>
          <fpage>1273</fpage>
          <lpage>1274</lpage>
          <pub-id pub-id-type="doi">10.1093/rheumatology/keg341</pub-id>
          <pub-id pub-id-type="pmid">14508054</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuruvilla</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Leitch</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Vickars</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Aplastic anemia following administration of a tumor necrosis factor-&#x3B1; inhibitor</article-title>
          <source>Eur J Haematol</source>
          <year>2003</year>
          <volume>71</volume>
          <fpage>396</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="doi">10.1034/j.1600-0609.2003.00115.x</pub-id>
          <pub-id pub-id-type="pmid">14667206</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marchesoni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arreghini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Panni</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Battafarano</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Uziel</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Life-threatening bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab</article-title>
          <source>Rheumatology</source>
          <year>2003</year>
          <volume>42</volume>
          <fpage>193</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="doi">10.1093/rheumatology/key051</pub-id>
          <pub-id pub-id-type="pmid">12509641</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seiderer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Goke</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ochsenkuhn</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Safety aspects of infliximab in inflammatory bowel disease patients</article-title>
          <source>Digestion</source>
          <year>2004</year>
          <volume>70</volume>
          <fpage>3</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1159/000080075</pub-id>
          <pub-id pub-id-type="pmid">15297773</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Ben-Salem C, Jeddi C, Fathalla N, et al. Infliximab-induced bone marrow aplasia and vasculitis. In: ISoP 9th annual Meeting, Reims, France, 2009, Abstract 10.</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobsen</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Fahlman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rusten</surname>
              <given-names>LS</given-names>
            </name>
          </person-group>
          <article-title>TNF-alpha, the great imitator: role of p55 and p75 TNF receptors in hematopoiesis</article-title>
          <source>Stem Cells</source>
          <year>1994</year>
          <volume>12</volume>
          <issue>Suppl 1</issue>
          <fpage>111</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="pmid">7535144</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="other">Schuettpelz LG, Link DC. Regulation of hematopoietic stem cell activity by inflammation. Front Immunol. 2013;4:204. doi:10.3389/fimmu.2013.00204. eCollection 2013.</mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dufour</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Corcione</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Svahn</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia</article-title>
          <source>Br J Haematol</source>
          <year>2001</year>
          <volume>115</volume>
          <fpage>1023</fpage>
          <lpage>1031</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2141.2001.03212.x</pub-id>
          <pub-id pub-id-type="pmid">11843845</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hara</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ando</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tsurumi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Moriwaki</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemia</article-title>
          <source>Eur J Haematol</source>
          <year>2004</year>
          <volume>73</volume>
          <fpage>10</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0609.2004.00259.x</pub-id>
          <pub-id pub-id-type="pmid">15182332</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dufour</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferretti</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bagnasco</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia</article-title>
          <source>Haematologica</source>
          <year>2009</year>
          <volume>94</volume>
          <fpage>1743</fpage>
          <lpage>1747</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2009.007815</pub-id>
          <pub-id pub-id-type="pmid">19586939</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dufour</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Giacchino</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ghezzi</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Etanercept as a salvage treatment for refractory aplastic anemia</article-title>
          <source>Pediatr Blood Cancer</source>
          <year>2009</year>
          <volume>52</volume>
          <fpage>522</fpage>
          <lpage>525</lpage>
          <pub-id pub-id-type="doi">10.1002/pbc.21886</pub-id>
          <pub-id pub-id-type="pmid">19061218</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fureder</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Valent</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches</article-title>
          <source>Leuk Lymphoma</source>
          <year>2011</year>
          <volume>52</volume>
          <fpage>1435</fpage>
          <lpage>1445</lpage>
          <pub-id pub-id-type="doi">10.3109/10428194.2011.568646</pub-id>
          <pub-id pub-id-type="pmid">21635205</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rezzoug</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tanner</surname>
              <given-names>MK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and function</article-title>
          <source>J Immunol</source>
          <year>2008</year>
          <volume>180</volume>
          <fpage>49</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.180.1.49</pub-id>
          <pub-id pub-id-type="pmid">18097003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Young</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Scheinberg</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Calado</surname>
              <given-names>RT</given-names>
            </name>
          </person-group>
          <article-title>Aplastic anemia</article-title>
          <source>Curr Opin Hematol</source>
          <year>2008</year>
          <volume>15</volume>
          <fpage>162</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="doi">10.1097/MOH.0b013e3282fa7470</pub-id>
          <pub-id pub-id-type="pmid">18391779</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramos-Casals</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brito-Zeron</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Munoz</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Autoimmune diseases induced by TNF-targeted therapies</article-title>
          <source>Medicine</source>
          <year>2007</year>
          <volume>86</volume>
          <fpage>242</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="doi">10.1097/MD.0b013e3181441a68</pub-id>
          <pub-id pub-id-type="pmid">17632266</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wiens</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Venson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Correr</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Otuki</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Pontarolo</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis</article-title>
          <source>Pharmacotherapy</source>
          <year>2010</year>
          <volume>30</volume>
          <fpage>339</fpage>
          <lpage>353</lpage>
          <pub-id pub-id-type="doi">10.1592/phco.30.4.339</pub-id>
          <pub-id pub-id-type="pmid">20334454</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <mixed-citation publication-type="other">Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Databases Syst Rev. 2013;(5):CD004525.</mixed-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murdaca</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Spano</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Contratore</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of etanercept in chronic immune-mediated disease</article-title>
          <source>Expert Opin Drug Saf</source>
          <year>2014</year>
          <volume>13</volume>
          <fpage>649</fpage>
          <lpage>661</lpage>
          <pub-id pub-id-type="doi">10.1517/14740338.2014.899579</pub-id>
          <pub-id pub-id-type="pmid">24654562</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
